<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092430</url>
  </required_header>
  <id_info>
    <org_study_id>V221-016</org_study_id>
    <secondary_id>2004_076</secondary_id>
    <nct_id>NCT00092430</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)</brief_title>
  <official_title>A Comparison of the Safety, Tolerability, and Immunogenicity of a Refrigerator-Stable Measles, Mumps, Rubella, and Varicella Combination Vaccine V221 (Refrigerated) Versus V221 (Frozen) in Healthy Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that an investigational refrigerated vaccine with
      measles, mumps, rubella, and varicella is well tolerated and has similar immune response when
      compared to a frozen vaccine with measles, mumps, rubella, and varicella.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2002</start_date>
  <completion_date type="Actual">June 9, 2003</completion_date>
  <primary_completion_date type="Actual">June 9, 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients demonstrating adequate antibody titers 6 weeks following administration</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers (GMT) 6 weeks post vaccination</measure>
  </secondary_outcome>
  <enrollment>1200</enrollment>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Varicella</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy children 12-23 months of age

        Exclusion Criteria:

          -  Previously had measles, mumps, rubella, or varicella

          -  Compromised immune system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Bernstein HH, Eves K, Campbell K, Black SB, Twiggs JD, Reisinger KS, Conti RM, Flodmark CE, Rombo L, Klopfer S, Sch√∂del F, Hartzel J, Kuter BJ; Refrigerator-Stable Formulation Study Group for ProQuad. Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live). Pediatrics. 2007 Jun;119(6):e1299-305. Epub 2007 May 14.</citation>
    <PMID>17502347</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 22, 2004</study_first_submitted>
  <study_first_submitted_qc>September 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2004</study_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Rubella</mesh_term>
    <mesh_term>Mumps</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

